EP3360572A4 - Développement de thérapie diététique dans le cancer - Google Patents

Développement de thérapie diététique dans le cancer Download PDF

Info

Publication number
EP3360572A4
EP3360572A4 EP16841134.6A EP16841134A EP3360572A4 EP 3360572 A4 EP3360572 A4 EP 3360572A4 EP 16841134 A EP16841134 A EP 16841134A EP 3360572 A4 EP3360572 A4 EP 3360572A4
Authority
EP
European Patent Office
Prior art keywords
cancer
development
dietary therapy
dietary
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16841134.6A
Other languages
German (de)
English (en)
Other versions
EP3360572A1 (fr
Inventor
Keisuke HAGIHARA
Kinya ASHIDA
Hidekazu Tonouchi
Kentaro Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka University NUC
Meiji Co Ltd
Original Assignee
Osaka University NUC
Meiji Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, Meiji Co Ltd filed Critical Osaka University NUC
Publication of EP3360572A1 publication Critical patent/EP3360572A1/fr
Publication of EP3360572A4 publication Critical patent/EP3360572A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP16841134.6A 2015-09-04 2016-09-02 Développement de thérapie diététique dans le cancer Pending EP3360572A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015175198 2015-09-04
PCT/JP2016/004023 WO2017038101A1 (fr) 2015-09-04 2016-09-02 Développement de thérapie diététique dans le cancer

Publications (2)

Publication Number Publication Date
EP3360572A1 EP3360572A1 (fr) 2018-08-15
EP3360572A4 true EP3360572A4 (fr) 2019-04-17

Family

ID=58186957

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16841134.6A Pending EP3360572A4 (fr) 2015-09-04 2016-09-02 Développement de thérapie diététique dans le cancer

Country Status (8)

Country Link
US (1) US10675262B2 (fr)
EP (1) EP3360572A4 (fr)
JP (2) JP7120564B2 (fr)
CN (1) CN107921133A (fr)
CA (1) CA2993773A1 (fr)
HK (1) HK1246152A1 (fr)
SG (1) SG11201800657VA (fr)
WO (1) WO2017038101A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921133A (zh) * 2015-09-04 2018-04-17 国立大学法人大阪大学 癌症的饮食疗法开发
WO2018186481A1 (fr) * 2017-04-06 2018-10-11 株式会社明治 Dispositif de surveillance de l'efficacité d'un régime cétogène
JP6968624B2 (ja) * 2017-04-06 2021-11-17 株式会社明治 ケトン食摂取量の管理方法
JPWO2018230487A1 (ja) * 2017-06-12 2020-04-09 株式会社明治 消化管症状を抑制するための組成物及び方法
JP7157743B2 (ja) * 2017-07-26 2022-10-20 株式会社明治 ケトン体生成促進剤
TW201920960A (zh) * 2017-09-22 2019-06-01 國立大學法人大阪大學 癌症生酮飲食治療之生物標記之開發
JP2019123672A (ja) * 2018-01-12 2019-07-25 株式会社明治 癌患者筋肉量減少抑制組成物
US20200147112A1 (en) * 2018-10-04 2020-05-14 Meiji Co., Ltd. Diet therapy of intractable cancer and medical diet suitable therefor
EP3941455A1 (fr) * 2019-03-22 2022-01-26 Société des Produits Nestlé S.A. Méthodes utilisant l'administration de triglycérides à chaîne moyenne (tcm) avant un repas pour augmenter la production de cétones à partir des tcm
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
JPWO2021060430A1 (fr) * 2019-09-27 2021-04-01
US20220394999A1 (en) 2019-12-19 2022-12-15 Hill's Pet Nutrition, Inc. Pet Food Compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014085652A1 (fr) * 2012-11-28 2014-06-05 University Of South Florida Ciblage du cancer par une thérapie métabolique et oxygène hyperbare
WO2014159500A1 (fr) * 2013-03-14 2014-10-02 University Of Florida Research Foundation, Incorporated Régulation du cancer à l'aide de composés naturels et/ou d'un régime

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080089981A1 (en) * 2006-10-17 2008-04-17 N.V. Nutricia Ketogenic diet
WO2011152707A1 (fr) * 2010-06-04 2011-12-08 N.V. Nutricia Formulation liquide stable à haute teneur en lipides
WO2012113415A1 (fr) * 2011-02-24 2012-08-30 N.V. Nutricia Composition pour régime cétogène pour le traitement de patients soumis à une chimiothérapie et/ou à une radiothérapie
US20140072654A1 (en) * 2011-12-23 2014-03-13 Savind, Inc. Cancer with metabolic therapy and hyperbaric oxygen
CN107921133A (zh) * 2015-09-04 2018-04-17 国立大学法人大阪大学 癌症的饮食疗法开发

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014085652A1 (fr) * 2012-11-28 2014-06-05 University Of South Florida Ciblage du cancer par une thérapie métabolique et oxygène hyperbare
WO2014159500A1 (fr) * 2013-03-14 2014-10-02 University Of Florida Research Foundation, Incorporated Régulation du cancer à l'aide de composés naturels et/ou d'un régime

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017038101A1 *

Also Published As

Publication number Publication date
HK1246152A1 (zh) 2018-09-07
US20180214410A1 (en) 2018-08-02
EP3360572A1 (fr) 2018-08-15
JP7168943B2 (ja) 2022-11-10
CN107921133A (zh) 2018-04-17
JPWO2017038101A1 (ja) 2018-06-14
JP2021101721A (ja) 2021-07-15
SG11201800657VA (en) 2018-02-27
CA2993773A1 (fr) 2017-03-09
US10675262B2 (en) 2020-06-09
WO2017038101A1 (fr) 2017-03-09
JP7120564B2 (ja) 2022-08-17

Similar Documents

Publication Publication Date Title
HK1246152A1 (zh) 癌症的飲食療法開發
HK1256283A1 (zh) 治療癌症有用的二氫咪唑並吡嗪酮衍生物
EP3368656A4 (fr) Thérapie anticancéreuse ciblée
EP3207162A4 (fr) Polythérapie destinée à être utilisée en cancérothérapie
EP3331612A4 (fr) Procédés et compositions destinés à la thérapie de tumeurs
HK1258319A1 (zh) 癌症療法
EP3258965A4 (fr) Polythérapie pour le traitement du cancer
EP3180000A4 (fr) Diagnostic et thérapie du cancer
EP2994148B8 (fr) Thérapie du cancer
EP2968260A4 (fr) Régulation du cancer à l'aide de composés naturels et/ou d'un régime
EP3091999A4 (fr) Compositions cellulaires améliorées et procédés pour la thérapie du cancer
EP3148526A4 (fr) Utilisation de l'éribuline dans le traitement du cancer
EP3008212A4 (fr) Méthodes de traitement du cancer
EP3286340A4 (fr) Compositions métagénomiques et méthodes pour la détection du cancer du sein
EP3062790A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3391885A4 (fr) Agent thérapeutique destiné au cancer du sein
EP3044593A4 (fr) Traitement du cancer
EP3016531A4 (fr) Compléments alimentaires et composition pour traiter le cancer
EP3256115A4 (fr) Polythérapie anticancéreuse
EP3169333A4 (fr) Méthodes et compositions pour améliorer un traitement anticancéreux
EP3227687A4 (fr) Récurrence de carcinome canalaire in situ (dcis) et cancer du sein invasif
EP3337784A4 (fr) Utilisation d'uréidomustine (bo-1055) dans le traitement du cancer
EP3439651A4 (fr) Améliorations apportées au traitement du cancer
EP3532638A4 (fr) Ciblage de microarn-101-3 p dans une cancérothérapie
GB201519734D0 (en) Cancer therapy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

PUAB Information related to the publication of an a document modified or deleted

Free format text: ORIGINAL CODE: 0009199EPPU

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAB Information related to the publication of an a document modified or deleted

Free format text: ORIGINAL CODE: 0009199EPPU

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190318

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/00 20060101ALI20190312BHEP

Ipc: A61P 43/00 20060101ALI20190312BHEP

Ipc: A61P 35/00 20060101ALI20190312BHEP

Ipc: A23L 33/115 20160101ALI20190312BHEP

Ipc: A61K 31/7016 20060101ALI20190312BHEP

Ipc: A61K 31/22 20060101ALI20190312BHEP

Ipc: A23L 33/00 20160101AFI20190312BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210127

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS